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Dear Editors:
Jehovah’s Witnesses (JWs) refuse
transfusions of homologous and
autologous blood and blood prod-
ucts that have been removed from
continuity with the body. They ac-
cept crystalloid solutions, synthetic
colloid solutions, hemoglobin sub-
stitutes such as perﬂuorocarbons or
artiﬁcial hemoglobin solutions, and
recombinant proteins such as eryth-
ropoietin or recombinant fac-
tor VIIa. Individual decisions need
to be made regarding administration
of puriﬁed fractions of plasma, such
as immunoglobulins and albumin, or
solid organ transplants. Liver trans-
plantation (LT) has been performed
in some highly selected and prepared
JW recipients [1]. In this report the
authors describe the successful
transplantation of a young adult
using a right liver lobe harvested
from her father.
A 17-year-old JW girl (60 kg,
180 cm) was suﬀering from end-
stage liver disease secondary to
cirrhotic autoimmune hepatitis.
Liver failure was complicated by
severe portal hypertension, hyper-
splenism, thrombocytopenia (15,000
platelets/mm3), and refractory asci-
tes. She refused the use of any blood
product other than puriﬁed albu-
min. In preparation for LT, she
underwent iron, folic acid, and
erythropoietin therapy, and spleen
embolization (Fig. 1), as descri-
bed [1], to increase hematocrit and
platelet count, respectively. At ﬁrst,
she was listed for cadaveric whole
liver transplantation. Her condition
deteriorated to Child–Pugh C liver
failure, and living-related LT was
considered. Her father (90 kg,
190 cm) proposed himself for dona-
tion and was compatible. Right lobe
procurement was considered to
provide suﬃcient liver mass to allow
immediate liver function, and the
procedure of living-related LT was
performed on 1 March 2002, using
the described technique [2]. For right
lobe harvesting, hemostasis of the
cut surface of the liver was achieved
by contact radiofrequency (Tissue-
Link Floating Ball, Tissuelink, Do-
ver, N.H.). The right lobe
(segments V–VIII) weighed 1244 g,
i.e., 2% of the recipient body weight.
In the recipient procedure, 20 lg/kg
recombinant activated factor VII
(Novoseven, Novo Nordisk, Den-
mark) was injected at the beginning
of dissection and at reperfusion. A
temporary surgical end-to-side por-
tocaval shunt was created to
decompress the splanchnic circula-
tory bed during dissection [3].
Continuous-circuit cell salvage,
high-dose aprotinin, and argon
beam coagulation were also used to
limit blood loss during the proce-
dure. Right lobe graft function was
immediate. No transfusion of allo-
geneic red cells, platelets, or fresh
frozen plasma was needed either in
the donor or the recipient, in accor-
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dance with the patients’ beliefs. Both
patients left the ward on postopera-
tive day 14, without any complica-
tion, and both were in perfect
condition with normal liver tests at
1 year of follow-up.Patients under-
going LT suﬀer from severe multiple
coagulation disturbances [4] and of-
ten require the use of large amounts
of blood products. Preparation of
JWs for LT may include erythro-
poietin therapy and subtotal arterial
spleen embolization to increase
hematocrit and platelet count [1].
Aprotinin showed eﬃcacy in reduc-
ing bleeding during LT [5]. The in-
traoperative use of recombinant
factor VIIa, which was shown to
correct coagulation in cirrhotic pa-
tients [6], may in part substitute for
fresh frozen plasma or other coagu-
lation factors. Bypass avoidance and
surgical portal decompression may
also reduce intraoperative blood
loss. Living-related LT allows the
procedure to take place at the best
time for both donor and recipient,
and this is particularly crucial in JW
patients. Particularly, the most
experienced surgeons and anesthesi-
ologists may then all be present in
the operating room.In JWs particu-
larly, living-related LT requires the
harvesting of suﬃcient liver mass to
avoid small-for-size syndrome and
primary graft dysfunction, as no
coagulation factors or blood may be
used in the early postoperative peri-
od. The relatively large liver mass
provided in this case may have been
a key factor for the success of living-
related LT in a JW.
Fig. 1 Abdominal computed tomodensitometry showing 80% spleen embolization of the
enlarged spleen and ascites
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